Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Cancer Immunotherapy Drug Discovery Outsourcing Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The cancer immunotherapy drug discovery outsourcing market has seen rapid expansion in recent years. It is forecast to grow from $1.66 billion in 2025 to $1.84 billion in 2026, at a compound annual growth rate (CAGR) of 10.9%. This historical growth can be attributed to several factors including rising global cancer prevalence, increasing research and development costs for immunotherapy drugs, limited in-house discovery capabilities, the expansion of biologics and monoclonal antibody pipelines, and the development of CRO infrastructure.
The cancer immunotherapy drug discovery outsourcing market size is anticipated to experience significant expansion over the next few years. It is forecast to grow to $2.64 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. This growth during the projected period can be ascribed to an accelerated need for precision immuno-oncology therapies, an increase in biotech startup formations, the escalating complexity of immunotherapy modalities, the imperative to shorten drug development timelines, and a rise in investment within outsourced discovery services. Noteworthy trends for the forecast period include an increase in the outsourcing of early-stage immunotherapy research, a growing requirement for specialized Contract Research Organization (CRO) expertise, the expansion of cell-based and immune assay services, enhanced collaboration between pharmaceutical and biotech companies, and the expedited development of next-generation immunotherapies.
Get A Free Sample Report With In-Depth Market Insights:
Cancer Immunotherapy Drug Discovery Outsourcing Market Growth Backed By Core Demand Fundamentals
The substantial expense associated with research and development is anticipated to drive the expansion of the cancer immunotherapy drug discovery outsourcing market in the future. These costs encompass significant financial outlays for scientific knowledge, cutting-edge lab facilities, intricate technological solutions, and innovative processes with inherent risks. Such expenditures are consistently increasing, driven by the growing intricacy of scientific endeavors and the necessity for highly specialized proficiencies. This market provides assistance to pharmaceutical and biotechnology firms by offering economical access to sophisticated research assets via contract research organizations (CROs). For example, as reported by The Office for National Statistics (ONS), a UK-based Statistics Authority, in August 2025, R&D spending within the UK reached $95.2 billion in 2023, marking a rise of $3.93 billion at current prices since 2022. Consequently, the considerable expense involved in internal research and development is propelling the expansion of the cancer immunotherapy drug discovery outsourcing market.
Cancer Immunotherapy Drug Discovery Outsourcing Market Breakdown By Product Type And Application
The cancer immunotherapy drug discovery outsourcing market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types
2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays
3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas
Subsegments:
1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants
3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy
4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy
Cancer Immunotherapy Drug Discovery Outsourcing Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the cancer immunotherapy drug discovery outsourcing market are adopting a strategic partnerships approach to hasten the development of new therapies. Such alliances advance the growth of the cancer immunotherapy drug discovery outsourcing market by granting access to sophisticated technologies, specific expertise, and integrated services, thus shortening development schedules and boosting the efficiency of introducing innovative cancer immunotherapies to clinical settings. For instance, in September 2025, Charles River Laboratories, a US-based contract research organization, formed a partnership with the Parker Institute for Cancer Immunotherapy, a US-based non-profit cancer research institute, with the goal of accelerating the creation of novel cancer treatments. This collaboration is centered on strengthening preclinical testing and manufacturing capabilities for advanced cell and gene therapies. By merging Charles River’s proficiency in contract research with the Parker Institute’s immunotherapy programs, the partnership endeavors to deliver groundbreaking cancer treatments to patients more effectively.
Cancer Immunotherapy Drug Discovery Outsourcing Market Company Landscape And Competitive Strategy
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc, Bio-Rad Laboratories Inc, QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc, ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Oncodesign Services, Reaction Biology Corporation
View The Full Cancer Immunotherapy Drug Discovery Outsourcing Market Report:
Cancer Immunotherapy Drug Discovery Outsourcing Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model